MDT

87.15

-1.56%↓

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

Начало・Списък с акции・Innoviva Inc

Innoviva Inc

Отворен

СекторЗдравеопазване

23.83 -0.5

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

23.8

Максимум

24.37

Ключови измерители
By Trading Economics
Приходи	152M 242M
Продажби	10M 118M
P/E Средно за сектора	6.976 66.418
Марж на печалбата	204.74
Служители	159
EBITDA	100M 208M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+56.65% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	58M 1.7B
Предишно отваряне	24.33
Предишно затваряне	23.83

Настроения в новините

By Acuity

46%

54%

154 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

18.57 / 18.75 Подкрепа & съпротива

Innoviva Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9.04.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9.04.2026 г., 23:14 ч. UTC

Пазарно говорене

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9.04.2026 г., 23:14 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

9.04.2026 г., 23:07 ч. UTC

Пазарно говорене

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9.04.2026 г., 22:54 ч. UTC

Пазарно говорене

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9.04.2026 г., 22:31 ч. UTC

Значими събития в новините

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9.04.2026 г., 22:31 ч. UTC

Значими събития в новините

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9.04.2026 г., 20:57 ч. UTC

Значими събития в новините

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9.04.2026 г., 20:55 ч. UTC

Печалби

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9.04.2026 г., 20:55 ч. UTC

Печалби

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9.04.2026 г., 20:55 ч. UTC

Печалби

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

9.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.04.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Rowan Digital Infrastructure Announces Strategic Recapitalization

9.04.2026 г., 20:25 ч. UTC

Придобивния, сливания и поглъщания

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9.04.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

9.04.2026 г., 19:30 ч. UTC

Значими събития в новините

How Digital Currencies Have Helped Iran -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Innoviva Inc Прогноза

Ценова цел

By TipRanks

56.65% нагоре

12-месечна прогноза

Среден 37 USD 56.65%

Висок 46 USD

Нисък 32 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Innoviva Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Innoviva Inc през последните 3 месеца.

Техническа оценка

By Trading Central

18.57 / 18.75Подкрепа & съпротива

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

154 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.